Cooley advised ViewPoint Therapeutics on closing its $35 million Series B funding round led by TPG’s new $2 billion social impact fund, The Rise Fund. The…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now